Dermapharm Holding SE (DMPHF) Stock

About Dermapharm Holding SE

Dermapharm Holding SE is an international pharmaceutical company specializing in off-patent branded medications, serving both domestic and global markets. Its business is structured across three distinct segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Imports, and Herbal Extracts. The company's comprehensive activities encompass the development, production, licensing, marketing, and distribution of its offerings. Its product range includes reputable generic drugs, non-prescription remedies, natural over-the-counter treatments, and a variety of other health products. These target diverse medical fields, such as vitamin and mineral supplementation, nutritional support, skin conditions (dermatology), allergies, pain relief, cardiovascular health, women's health (gynecology), and urological issues. Key brands in its portfolio feature Dekristol, Dekristolvit, Allergovit, and Tromcardin. Additionally, Dermapharm provides medical devices like bite away and Herpotherm, alongside specific treatments such as the Momekort nasal spray for allergy symptoms and Azedil, available as a nasal spray or eye drops. Within its Parallel Imports division, Dermapharm brings original pharmaceuticals to market under the axicorp brand. The Herbal Extracts segment supplies natural active ingredients and botanical extracts primarily for phytopharmaceuticals, nutraceuticals, and cosmetic applications. The company's distribution network reaches pharmaceutical wholesalers, individual pharmacies, hospitals, and health food stores. Founded in 1991 and headquartered in Grünwald, Germany, Dermapharm Holding SE operates as a subsidiary of Themis Beteiligungs-Aktiengesellschaft.

Dermapharm Holding SE is headquartered in DE.

Dermapharm Holding SE (DMPHF) stock trades at $53.00 with a market capitalization of $2.63B. The stock is valued at a price-to-earnings (P/E) ratio of 16.91, price-to-book of 3.32, price-to-sales of 1.93. Over the past 52 weeks the stock has ranged between $39.56 and $53.00, and currently trades at its 52-week high. It pays a dividend yielding 1.91%.

On profitability, Dermapharm Holding SE generates a return on equity (ROE) of 21.44% — well above the market average, a sign of a high-quality business, return on capital employed of 12.42%, an operating margin of 20.01%, a net profit margin of 12.34%.

Official website: www.dermapharm.de